Clinical Trials Directory

Trials / Completed

CompletedNCT06481488

A Study of E2086 in Healthy Adult Participants

A Randomized, Double-Blind, Placebo-Controlled, Combined Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Single Dose Study to Assess Food Effect of E2086 in Healthy Adult Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Eisai Inc. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The primary purpose of the study is to evaluate the safety and tolerability following multiple ascending doses of E2086 in healthy adult participants.

Conditions

Interventions

TypeNameDescription
DRUGE2086E2086 tablets.
DRUGPlaceboE2086 matched placebo tablets.

Timeline

Start date
2024-06-25
Primary completion
2024-12-13
Completion
2024-12-13
First posted
2024-07-01
Last updated
2025-01-16

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06481488. Inclusion in this directory is not an endorsement.